e look forward to working with Biogen on completing the clinical program and preparing for what we hope is a positive regulatory review, said B. Lynne Parshall, chief operating officer at Ionis Pharmaceuticals. Nusinersen is the first antisense drug from our neurological disease franchise to advan
Date: Aug 01, 2016
Category: Health
Source: Google
Isis Phamaceuticals changes name to distance itself from terrorist group
"Our goal is to create medicines that will save patients' lives, and we are proud to be at the forefront of creating innovative medicines," said Lynne Parshall, chief operating officer at Ionis Pharmaceuticals. "We decided to change our company name because, when people see or hear our name, we want
Date: Dec 19, 2015
Category: Business
Source: Google
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Receives Consensus Rating of "Buy ...
70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO B Lynne Parshall sold 12,436 shares of ISIS Pharmaceuticals stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $40.75, for a total transaction of $506,767.
Date: Dec 07, 2015
Category: Health
Source: Google
Vetr Inc. Downgrades ISIS Pharmaceuticals to Buy (ISIS)
In other news, COO B Lynne Parshall sold 6,218 shares of the companys stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $57.01, for a total transaction of $354,488.18. The sale was disclosed in a legal filing with the SEC, which can be accessed thro
Date: Sep 11, 2015
Category: Business
Source: Google
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief ...
Her expertise and knowledge of the severe and rare/cardiovascular space coupled with her business development and global marketing background is ideally suited for leading Akcea," said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals. "The formation of Akcea Therapeutics comes
B Lynne Parshall, chief operating officer atIsis Pharmaceuticals, said:"We are the leader in RNA-targeted therapeutics and our innovation and the successes of our pipeline drugs enable us to form collaborations, like this one, with leaders in specific therapeutic areas.
Date: Jan 06, 2015
Category: Business
Source: Google
Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
Sarah's business and marketing expertise in life sciences will complement our strong research and development organization and help ensure that we are maximizing the potential of our assets," said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals. "I am very pleased to have Sarah
This collaboration broadens the utility of our drug discovery technology to new targets in the GI tract and expands the administration of antisense drugs to local delivery, including oral delivery, to the gut," B. Lynne Parshall, Isis Pharmas COO, said in a statement.